Study participant measuring reading capacity post-retinal implant
Moorfields Eye Hospital
Individuals experiencing significant vision impairment can regain the ability to read, thanks to a compact wireless chip implanted in one eye along with advanced glasses.
Age-related macular degeneration (AMD) is a prevalent condition that impacts central vision and tends to progress over time. While the precise cause remains unknown, this condition arises from damage to the light-sensitive photoreceptor cells and neurons located in the central retina, leading to difficulties in facial recognition and reading. Available treatments are primarily designed to slow down the progression.
An advanced form of AMD referred to as geographic atrophy typically allows individuals to retain some photoreceptor cells that facilitate peripheral vision, along with sufficient retinal neurons to relay visual information to the brain.
Leveraging this capability, Daniel Palanker and his team at Stanford University in California created the PRIMA device. This system includes a small camera mounted on the glasses, which captures images and projects them through infrared light onto a 2-by-2-millimeter solar-powered wireless chip implanted at the rear of the eye.
The chip then transforms the image data into electrical signals, which the retinal neurons transmit to the brain. Infrared light is employed for this process as it is invisible to the human eye, thereby ensuring it does not interfere with any remaining vision. “This allows patients to utilize both the prosthesis and their peripheral vision simultaneously,” explains Palanker.
To evaluate its efficacy, researchers enlisted 32 participants aged 60 and above, all suffering from geographic atrophy. Their visual acuity in at least one eye was below 20/320—meaning they could see what a person with 20/20 vision could see at 320 feet (97.5 meters) only at 20 feet (6 meters).
The team initially implanted a chip in one of the participant’s eyes. After a waiting period of four to five weeks, the volunteers began using the glasses in their everyday activities. The glasses enabled them to magnify their view up to 12 times and adjust brightness and contrast as needed.
After a year of using the device, 27 of the participants managed to read again and recognize shapes and patterns. They also noted an average improvement of five lines on a standard eye chart compared to their initial findings. Some participants were able to achieve 20/42 vision.
“Witnessing them progress from reading letters to full words brought immense joy to both sides. One patient expressed, ‘I believed my eyes were irreparably damaged, but now they’re revitalizing,'” shares Jose Alan Sahel from the University of Pittsburgh School of Medicine.
While stem cell therapy and gene therapy may potentially restore vision lost due to AMD, these approaches are still in early experimental trials. PRIMA stands out as the first artificial eye designed to restore functional vision in individuals with the condition, allowing them to perceive shapes and patterns.
Approximately two-thirds of the volunteers experienced temporary side effects, such as increased intraocular pressure, as a result of the implants; however, this did not hinder their vision improvement.
Comparison of a trial participant’s eye (left) and eye with retinal implant (right)
Science Co., Ltd.
“This research is both exciting and significant,” remarks Francesca Cordeiro from Imperial College London. “It provides hope for delivering vision improvements that have previously seemed more like science fiction.”
The improved visibility experienced by participants is limited to black and white. “Our next objective is to develop software to provide grayscale resolution and enhance facial recognition,” states Palanker. Nevertheless, researchers do not anticipate achieving color vision in the near future.
Palanker also aims to increase PRIMA’s resolution, which is currently constrained by pixel size and the total count that can be included on a chip. Testing a more advanced version in rats is underway. “This current version equates to human vision of 20/80, but electronic zoom can enable vision as sharp as 20/20,” he explains.
Deep brain stimulation is already utilized for Parkinson’s disease
Living Art Enterprise/Science Photo Library
Brain implants capable of detecting pain and responding with deep brain stimulation may provide relief for individuals suffering from previously untreated chronic pain.
Deep brain stimulation (DBS) involves using tiny electrodes to stimulate the brain, showing potential but also yielding inconsistent outcomes. The conventional method has typically applied a one-size-fits-all targeting of brain regions, despite indications that pain can stem from varying circuits in different individuals.
Thus, Prasad Shirvalkar and his team at the University of California, San Francisco, explored whether a personalized system might yield better results. In their study, six individuals with previously untreated chronic pain had their intracranial brain activity recorded and stimulated across 14 locations in the brain for ten days.
Out of five participants, the researchers pinpointed specific sites and stimulus frequencies that resulted in the most significant pain relief. While one participant noted no substantial relief, he could hold his wife for the first time in years, a notable improvement in his physical capabilities.
The research team employed machine learning to analyze and differentiate the electrical patterns associated with high and low pain levels. Consequently, they implanted permanent DBS electrodes personalized for each participant to monitor brain activity and optimize stimulation for pain detection and deactivation during sleep.
After six months of adjustments, each device underwent a trial where participants experienced real personalized stimulation for three months, followed by fake stimulation for another three months, or vice versa. The false stimulation targeted non-ideal locations with very low frequencies, and pain metrics were monitored multiple times daily throughout the trial.
On average, authentic stimulation led to a 50% reduction in daily pain intensity compared to the increase observed with spurious stimulation. Notably, the daily step counts increased by 18% during the false stimulation phase. Participants also reported fewer depressive symptoms and less pain interfering with daily life when undergoing real stimulation. These improvements persisted for over 3.5 years post-trial.
“This significant study employs the latest tools,” remarks Tim Dennison from Oxford University.
A previous challenge with DBS technology involved habituation; the brain would adapt to continuous stimulation, diminishing its effectiveness. Dennison suggests that extended benefits may arise from stimulating participants only when pain levels are elevated. The next phase will involve comparing adaptive versus constant stimuli to evaluate differences in outcomes.
“The other major hurdle lies in the economic feasibility and scalability of this method,” Dennison notes.
A man who underwent brain stimulation had previously tried 20 treatments for his depression
Damien Fair et al./cc-by 4.0
Men suffering from severe depression for over 30 years have seemingly found relief through a personalized brain “pacemaker” designed to selectively stimulate various brain regions.
“He’s felt joy for the first time in years,” states Damien Fair from the University of Minnesota.
Treatment-resistant depression is often characterized by minimal improvement after trying at least two antidepressants. While procedures like electroconvulsive therapy (ECT) may provide some benefits, they don’t always yield relief. “They’re effective for all sizes. You’ll target the same brain area,” Fair explains. Yet, as every brain is unique, he often doesn’t hit the exact target needed for individual relief.
Fair and his team have now created a tailored method for a 44-year-old man, who was first hospitalized for depression at 1 PM. He had attempted 20 different treatments, including antidepressants, therapy, ECT, and more, all without lasting success. “It’s one of the most severe depression cases I’ve seen; he has attempted suicide three times,” Fair notes.
Initially, the researchers conducted a 40-minute MRI scan to delineate the boundaries of four brain activity networks linked to depression. This particular network in the man was found to be four times more active than that of individuals without depression, potentially exacerbating his symptoms, according to Fair.
The team then surgically implanted clusters of four electrodes at these defined boundaries, entering through two small openings in the skull. Just three days later, they began sending weak electrical pulses through wires attached to the electrodes, stimulating each brain network separately.
Upon stimulating the first network—default mode, related to introspection and memory—the man cried tears of joy. “I felt so much better,” Fair recalls.
Stimulation of the Action Mode and Salience Networks also led to reduced feelings of anxiety, while the team noticed enhanced focus when targeting the parietal networks involved in decision-making.
Using the man’s feedback, the team connected the electrode wires to tiny batteries placed just beneath the skin near the collarbone, allowing him to maintain these benefits outside the hospital. This setup acts like a “brain pacemaker,” as Fair describes it, stimulating various networks for a minute each day.
For six months, the man utilized an app linked to the pacemaker to alternate between different stimulation patterns crafted by the team every few days. He also documented his depression symptoms daily. The team optimized the stimulation based on this data during the first six months post-surgery.
Even seven weeks post-surgery, the man reported no suicidal thoughts. By the nine-month mark, he was in remission as per the Hamilton Depression Rating Scale. This improvement persisted for over two and a half years, apart from a brief period when his symptoms slightly recurred after contracting Covid-19.
“This is an incredible outcome,” states Mario Juruna from King’s College London. “It serves as a crucial proof of concept for patients unable to tolerate traditional depression treatments.”
It’s plausible that the expanded salience network of the man played a role in the treatment’s success. This is often present in depression; however, it’s premature to conclude if individuals with a lower level of salience network expansion would respond similarly, Juruena states.
To confirm the safety and effectiveness of this approach, randomized controlled trials assigning various individuals with depression to either stimulation or placebo will be necessary, according to Juruena. The team aims to conduct these trials within two years after testing the method on additional individuals, according to Fair.
If you need someone to listen, reach out: Samaritans in the UK at 116123 (Samaritans.org); US 988 Suicide & Crisis Lifeline: 988 (988lifeline.org). Visit bit.ly/suicidehelplines for resources in other countries
Can flashy technology directly influence the regulation of hormones within your body and mind? By the year 2035, a myriad of options had emerged on the market. Morning pick-me-ups? Do you stimulate desire when you settle down for the night? Or perhaps a period of immunity to discomfort? It’s all now within reach.
This innovation began in 2027, when daily treatments for severe surface and internal abrasions were developed within a living dressing. This dressing belonged to a class of engineered Biological Materials (ELM) that produce enzymes and antibiotics to expedite healing.
ELM is also utilized in the production of fermented beverage kombucha, inspired by the biofilm that can form in vinegar. Known as the “mother” layer, biofilms are living substances and symbiotic cultures of bacteria and yeast (Scoby). In vinegar, Scoby transforms alcohol into acetic acid, while in kombucha, it generates acetic acid and other compounds from sweetened tea. However, crafting unique synthetic scobies (sin-sobies) with gene-edited yeasts and bacteria can generate the essential enzymes, nutrients, and hormones. In 2021, a team from Imperial College London developed programmable Scobys using Baker’s yeast, easily modified to produce various compounds.
The first widely adopted Syn-Scoby was a medical material, stored in a dormant state within emergency kits and surgical units. When required, the material, now referred to as the Heal Me patch, is extracted and applied to the affected area. Once exposed to oxygen, the yeast is reactivated to convert its cellulose matrix into the necessary compounds. These include protein-degrading enzymes that swiftly dismantle dead and damaged tissues, alongside other enzymes that mitigate pain and inflammation, thereby accelerating recovery.
Following successful medical applications, Syn-Scobys were devised in the 2030s for numerous uses, extending from contaminant detection in the environment to delivering vital nutrients, enzymes, and hormones. Syn-Scobys replaced the bionic pancreas utilized by individuals with type 1 diabetes for insulin production and blood glucose control. Other variants emitted a luminescent protein upon identifying specific contaminants, metals, or pathogens in the surroundings.
Military researchers created patches that produce adrenaline and testosterone to alleviate pain and enhance aggression. However, Heal Me patches had direct access to the bloodstream via human wounds, exposing the compounds to digestive enzymes before absorption. To counter this, scientists engineered patches intended to be implanted in the thighs or abdomen. When soldiers required a boost, an activating enzyme was injected at the implant site. This initiating enzyme activates the Syn-Scoby within the patch and releases the desired compounds into the bloodstream.
Activate your customized living implants to enhance focus, aggression, stamina, and pain tolerance.
Customized living implants can be triggered as needed to amplify focus, aggression, endurance, and pain resistance. Recreational Synscobi is designed to generate stimulants, psychedelics, and libido enhancers.
The array of embedded patches is now available for immediate use. They secrete leptin to mimic solid leptin and inhibit ghrelin, which triggers hunger. Another variant allows live implants to produce semaglutide drugs such as Mounjaro, Wegovy, and Ozempic to suppress the urge to eat or drink, focusing on generating drugs like modafinil and oxiracetam that enhance cognitive function and memory retention.
For recreational purposes, psychoactive compounds like psilocybin are secreted, easily synthesized from gene-edited yeast. Users are filled with oxytocin and serotonin, fostering feelings of love, joy, and sexual desire. Dream Me facilitates controllable dreaming and stages of restful sleep, offering two options: Lucid and Black Out.
The most exclusive and sought-after implant was the Juve Me series, which generated various anti-aging compounds known as cytopathy and gathered senomorphic substances such as rapamycin and metformin that clear senescent cells and rejuvenate aged cells. Unlike many other ELMs, which have a temporary existence within the body before being metabolized, Juve Me implants were purposefully designed to be self-sustaining. It represents a symbiotic being living harmoniously within a fortunate individual, supplying nutrients essential for the implant’s longevity and vitality.
Hat Tips for Iain M. Banks’s culture The novels serve as inspiration for my symbiotic implants, which align with the bank’s concept of “Granding.”
Rowan Hooper is the podcast editor for New Scientist and author of How to Spend $1 Trillion: These are 10 global issues that can realistically be addressed. Follow him on Bluesky @rowhoop.bsky.social
Retinal implants have shown potential in restoring vision in blind mice, indicating that they may eventually help those with conditions like age-related macular degeneration, where photoreceptor cells in the retina deteriorate over time.
Shuiyuan Wang from Fudan University in China and his team developed a retinal prosthesis composed of metal nanoparticles that replicate the function of lost retinal cells, converting light into electrical signals to be sent to the brain.
In their experiments, the researchers administered nanoparticles into the retinas of mice that had been genetically modified to be nearly completely blind.
They restricted water access for three days to both the modified blind mice and those with normal vision. Subsequently, they trained all mice to activate a 6cm wide button on a screen to receive water.
Following training, each mouse underwent 40 testing rounds. The fully sighted mouse pressed the button successfully 78% of the time. Mice with implants achieved a 68% success rate, while untreated blind mice only managed 27%. “That presents a very noticeable effect,” stated Patrick DeGenard, who wasn’t involved in the research but is affiliated with Newcastle University in the UK.
After 60 days, researchers observed minimal signs of toxicity from the implants in the mice. However, Degenaar emphasized the need for long-term safety data, stating, “For clinical application, extensive animal testing lasting approximately five years will be necessary.”
“Patients with age-related macular degeneration and retinitis pigmentosa could benefit from this prosthetic,” noted Leslie Askew from the University of Surrey, UK, who was not part of the study.
Degenaar also remarked that justifying this solution for age-related macular degeneration patients is complex, as they possess a degree of vision that may not warrant the risks associated with implanting prosthetics.
Furthermore, he noted that mice generally have inferior vision compared to humans, raising uncertainty about how beneficial the findings will be for people until comprehensive clinical trials are conducted.
ohRan Knowles, a British teenager with a severe form of epilepsy called Lennox-Gastaut syndrome, became the first person to try the new brain implant last October, with astonishing results: his daytime seizures reduced by 80 percent.
“The device has had a huge impact on my son's life as he no longer falls and injures himself like he used to,” said his mother, a consultant paediatric neurosurgeon at Great Ormond Street Hospital in London (Gosh), who implanted the device. She added that there has been a huge improvement in her son's quality of life as well as his cognitive abilities. He is more alert and outgoing.”
Oran's neurostimulator is implanted under the skull and sends constant electrical signals deep into the brain with the aim of blocking the abnormal impulses that cause seizures.The implant, called Picostim, is about the size of a cell phone battery, is charged through headphones and works differently during the day and at night.
“The device has the ability to record from the brain, to measure brain activity, and we can use that information to think about how to improve the effectiveness of the stimulation that children are receiving,” says Tisdall. “What we'd really like to do is to make this treatment available on the NHS.”
As part of the trial, three children with Lennox-Gastaut syndrome will be fitted with the implant in the coming weeks, with a full trial planned for 22 children early next year. If the trial is successful, academic sponsors Ghosh and University College London plan to apply for regulatory approval.
Tim Denison, a professor of engineering science at the University of Oxford and co-founder and chief engineer at Amber Therapeutics, a London-based company that developed the implant in collaboration with the university, hopes that the device will be available on the NHS and around the world within the next four to five years.
The technology is one of a number of neural implants being developed to treat a range of conditions, including brain tumors, chronic pain, rheumatoid arthritis, Parkinson's disease, incontinence and tinnitus. These devices are more sophisticated than traditional implants in that they not only decode the brain's electrical activity but also control it, and this is where Europe is racing against the US to develop life-changing technology.
The latest generation of brain implants can not only detect brain activity but also control it. Photo: UCL
Amber isn't the only company working on brain implants to treat epilepsy. California-based Neuropace has developed a device that responds to abnormal brain activity and has been cleared by US regulators for use by people aged 18 and over. But the battery is not rechargeable and must be surgically replaced after a few years. Other devices are implanted in the chest with wires running to the brain that must be reinserted as the child grows.
When most people think of brain chips, they think of Neuralink, another California-based startup from Elon Musk that just implanted a brain chip in a second patient with a spinal cord injury. The device uses tiny wires thinner than a human hair to capture signals from the brain and translate them into actions.
The first recipient, Noland Arbaugh, was in January and is paralyzed from the neck down. Some of the wires had shifted and the implant needed to be adjusted. The implant allows Arbaugh to control a mouse cursor on a computer screen with his mind, as if he were watching a movie. Star Wars A Jedi who “uses the Force.”
Other US companies, such as Syncron, backed by Bill Gates and Jeff Bezos, have also recently implanted brain-computer interfaces (BCIs) in people who cannot move or speak.
But scientists say these implants simply decode electrical signals. In contrast, a number of companies in the U.S., Britain and Europe, like Amber, are working on so-called “BCI therapy,” or modulating signals in deep brain stimulation to treat disease. Amber's implants are also being used in academic trials for Parkinson's disease, chronic pain and multiple system atrophy, a condition that gradually damages nerve cells in the brain. The company is also sponsoring an early trial in Belgium to treat incontinence, with promising results.
Professor Martin Tisdall led the team that gave Oran Noorsson, who suffers from severe epilepsy, the implant last October. Photo: UCL
A different kind of technology will be tested in humans in clinical trials starting in a few weeks, using the first brain implant made from graphene, a “miracle material” discovered 20 years ago at the University of Manchester.
Medical teams at Salford Royal Infirmary will implant a device with 64 graphene electrodes into the brains of patients with glioblastoma, a fast-growing form of brain cancer. The device will stimulate and read neural activity with high precision, to spare other parts of the brain while removing the cancer. The implant will be removed after surgery.
“We use this interface to map out where the glioblastoma is and then remove it. [cut it out] “Without affecting areas of function such as language or cognition,” says Carolina Aguilar, co-founder and CEO of InBrain Neuroelectronics, the Barcelona-based company that developed the implant in collaboration with the Catalan Institute of Nanoscience and Nanotechnology and the University of Manchester.
Traditionally, platinum and iridium have been used in implants, but graphene, made from carbon, is ultra-thin, harmless to human tissue, and can be decoded and modulated very selectively.
InBrain plans to conduct clinical trials of similar artificial intelligence-powered implants in people with speech disorders caused by Parkinson's disease, epilepsy and stroke.
Professor Costas Kostarellos, head of nanomedicine at the University of Manchester, co-founder of InBrain and principal investigator on the glioblastoma trial, says the company's goal is to “develop more intelligent implantable systems”.
Equipped with AI, the device, with 1,024 electrical contacts, “will help provide optimal treatment for each patient without the neurologist having to program all those contacts individually, as they do today,” he says.
InBrain has partnered with German pharmaceutical company Merck to use its graphene device to stimulate the vagus nerve, which controls many bodily functions including digestion, heart rate and breathing, to treat severe chronic inflammatory, metabolic and endocrine diseases such as rheumatoid arthritis.
Galvani Bioelectronics, founded in 2016 by the UK's second-largest pharmaceutical company GSK and Alphabet's Verily Life Sciences, has a pioneering treatment that treats rheumatoid arthritis by stimulating the splenic nerve. Galvani has begun clinical trials with patients in the UK, US and the Netherlands, with first results expected within the next 6-12 months.
Bioelectronics, which combines biological sciences and electrical engineering, is a market worth $8.7 billion today and is predicted to reach more than $20 billion (£15 billion) by 2031. According to Verified Market Research:The field focuses on the peripheral nervous system, which transmits signals from the brain to organs and from organs to the brain. When brain-focused neuromodulation and BCIs are added, Aguilar believes the overall market could be worth more than $25 billion.
While U.S. neuromodulation companies are making waves with devices targeting chronic pain and sleep apnea, a growing number of European startups are also working on the technology. MintNeuro, a spinout from Imperial College London, Working on developing next-generation chips The company is developing an implant that can be combined into a smaller implant and has partnered with Amber. With the support of an Innovate UK grant, its first project will be to develop an implant to treat mixed urinary incontinence.
Geneva-based Neurosoft has developed a device that uses a thin metal film attached to stretchy silicon – soft enough to put less pressure on the brain and blood vessels – to target severe tinnitus, which affects 120 million people worldwide.
“Tinnitus begins with ear damage, typically caused by loud noise, but it can also cause changes in the wiring of the brain, making it effectively a neurological disorder,” said Nicholas Batsikouras, the company's chief executive officer.
Founded in 2009 by 13 neurosurgeons, neurologists, engineers and other scientists from the Policlinico Research Center and the University of Milan, Neuronica has developed a rechargeable deep brain neurostimulator that can be used to treat Parkinson's disease. The device provides closed-loop stimulation and adapts moment-to-moment to the patient's condition, and is currently being tested on patients.
“Europe and the UK can compete head-to-head with the US when it comes to getting treatments onto the NHS and distributing them around the world,” Denison said. “It's a fair competition and we're going to give it our all.”
I lost to a cyborg. When I played the online game WebGrid, using my finger on my laptop’s trackpad to click squares that appear unpredictably on a grid, I was able to beat him at 42 beats per minute. When Noland Arbaugh, a self-described cyborg, played the game, using a chip implanted in his brain to send telepathic signals to a computer, his speed was 49.
Arbaugh was paralyzed from the neck down in 2016. In January, he became the first person to be surgically implanted with a chip made by Neuralink, a company founded by Elon Musk. Since then, Arbaugh has been able to use his mind to control his phone and computer, surf the web, and play games. civilization And chess.
But Neuralink is not the only company using brain-computer interfaces (BCIs) to blend the human brain with machines. Thanks to a series of trials, many people paralyzed by spinal cord injuries, strokes and movement disorders are regaining lost abilities. These successes have surprised some researchers, says Jamie Henderson, a neurosurgeon at Stanford University in California. “It’s been an incredible advance.”
Where that will take us remains to be seen. Musk recently mused about developing bionic implants that could compete with artificial superintelligence. Others see deeper implications: “In the future, we will be able to manipulate human perception, memory, behavior and identity,” says Rafael Yuste of Columbia University in New York.
But while BCIs are undoubtedly impressive, as Arbaugh’s WebGrid scores show, the relationship between brain activity, thoughts, and behavior is incredibly complex. Memory…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
